SAN DIEGO, Calif. (Ivanhoe Newswire) - A breakthrough in bladder cancer treatment is helping to save more lives. The American Cancer Society estimates that 83,000 new cases of bladder cancer will be ...

Shares of ImmunityBio IBRX were up 3% in after-market trading yesterday after the company announced that the FDA accepted its ...

Merck (MRK) shares rose nearly 5% in early trade on Friday after the company said a European medicines committee issued a ...

Structured behavioral therapy focused on pelvic floor muscle exercise was noninferior to treatment with solifenacin for alleviating overactive bladder symptoms in patients with Parkinson’s disease (PD ...

Stock Moves Higher Following Patent Announcement Shares of ImmunityBio (NASDAQ:IBRX) gained 4.5% in premarket trading on ...

Detalimogene voraplasmid lead to numerous durable complete responses with favorable safety ...

When we think of smoking-related cancers, lung cancer usually comes to mind. But smoking is also a major driver for bladder cancer. Now, a new treatment has come to Philadelphia to help more patients ...

A new survey undertaken by the Harris Poll for Johnson & Johnson has shown how standard forms of surgery and treatment for ...

A breakthrough in bladder cancer treatment is offering new hope to patients. The American Cancer Society estimates that 83,000 new cases of bladder cancer will be diagnosed this year, with nearly ...

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced new survey data highlighting the ...

A new study may pave the way toward more personalized treatments for patients with high-risk bladder cancer, according to a study published in European Urology.